Merck/Schering: The Next Wave Of Consolidation
This article was originally published in The Pink Sheet Daily
Executive Summary
$41.1 bil. acquisition will create a cardiovascular powerhouse, buffer Merck against patent expirations of Singulair, Cozaar/Hyzaar and generate $3.5 bil in savings.